Weatherall Mark, Clay Jennifer, James Kate, Perrin Kyle, Shirtcliffe Philippa, Beasley Richard
University of Otago, Otago, New Zealand.
Respirology. 2009 Sep;14(7):983-90. doi: 10.1111/j.1440-1843.2009.01589.x.
The risk of cataracts associated with the long-term use of inhaled corticosteroids (ICS) is poorly recognized, yet may be of major public health importance. The aim of this study was to determine the dose-response relationship of ICS use and risk of cataracts in adults.
A systematic review and meta-analysis was performed of case-control studies of cataracts and ICS use, which included at least two doses of ICS and in which the number of cases and controls using each dose of ICS was reported. The primary outcome variable was risk of cataracts.
Four case-control studies were identified, with a total of 46 638 cases and 146 378 controls. There was a significant relationship between the risk of cataracts and ICS dose, with a random effects pooled odds ratio for risk of cataracts per 1000 microg increase in daily beclomethasone dipropionate dose of 1.25 (95% CI: 1.14-1.37).
The risk of cataracts was increased by approximately 25% for each 1000 microg per day increase in the dose of beclomethasone dipropionate or equivalent. These findings reinforce the importance of prescribing within the therapeutic dose-response range for ICS in asthma and the need to determine the dose-response relationship for the efficacy of ICS in COPD. Screening for the presence of cataracts could usefully be undertaken in older subjects with asthma and COPD, particularly current or ex-smokers.
长期使用吸入性糖皮质激素(ICS)与白内障风险之间的关系尚未得到充分认识,但可能具有重大的公共卫生意义。本研究旨在确定成人使用ICS与白内障风险之间的剂量反应关系。
对白内障与ICS使用的病例对照研究进行系统评价和荟萃分析,这些研究至少包括两种剂量的ICS,且报告了使用每种剂量ICS的病例数和对照数。主要结局变量为白内障风险。
共纳入4项病例对照研究,总计46638例病例和146378例对照。白内障风险与ICS剂量之间存在显著关系,每日丙酸倍氯米松剂量每增加1000微克,白内障风险的随机效应合并比值比为1.25(95%CI:1.14 - 1.37)。
丙酸倍氯米松或等效药物剂量每天每增加1000微克,白内障风险增加约25%。这些发现强化了在哮喘治疗中按照ICS的治疗剂量反应范围用药的重要性,以及确定ICS在慢性阻塞性肺疾病(COPD)中疗效的剂量反应关系的必要性。对于患有哮喘和COPD的老年受试者,特别是当前吸烟者或既往吸烟者,进行白内障筛查可能会很有用。